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An improved understanding of currently used bioceramics in human implants and in bone replacement
materials could contribute significantly to the design of new generation prostheses and post-operative
patient management strategies. Overall, the benefits of advanced ceramic materials in biomedical applica-
tions have been universally appreciated, specifically, in terms of their strength, biocompatibility and wear
resistance. However, the amount of supporting data is not large and the continuous development of new
characterization tools is pertinent for better understanding of the microstructure-properties relationship
and in general for obtaining new directives for their further improvement. This paper gives an overview and
re-examines key-issues which concern both processing and applications of ceramics as biomaterials. With
doing this, we attempt to bring to the attention of the ceramic community the issues in current bioceramics.
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1. Introduction
From early as a century ago artificial materials and
devices have been developed to a point where they can
replace various components of the human body. These new
artificial materials have the ability to function within the
harshest of environments, and within the living tissue they
can operate without any adverse reaction or rejection by the
body. These are known as 'Biomaterials.' Biomaterials by
definition are "a non-drug substance suitable for inclusion in
systems which augment or replace the function of bodily
tissues or organs." These materials should be capable of
being in contact with bodily fluids and tissues for prolonged
periods of time, whilst eliciting little if any adverse
reactions.!'
Some of the earliest biomaterial applications were as far
back as ancient Phoenicia where loose teeth were bound
together with gold wire and ligatures were used for tying ar-
tificial ones to neighbouring teeth. In the early 1900's bone
plates were successfully implemented to stabilise bone frac-
tures and to accelerate their healing. While by the time of
the 1950 to 60's, blood vessel replacement experiments
were in clinical trials and artificial heart valves and hip joints
were in development.
Even in the preliminary stages of this field, surgeons and
engineers identified materials and design problems that
resulted in premature loss of implant function through
mechanical failure, corrosion or inadequate biocompatibility
of the component. These observations determined that the
key factors in a biomaterial usage are its biocompatibility,
biofunctionality, and availability to a lesser extent.
Ceramics may be ideal candidates with respect to all the
above functions, except for their brittle behaviour. In par-
ticular, the absence of an intrinsic toughening mechanism,
which on the microscopic scale allows local stress release by
plastic deformation, represents the most remarkable differ-
ence between biogenic hydroxyapatite and synthetically
prepared hydroxyapatite. In this paper, we shall revisit the
presently available bioceramics, their preparation methods,
their mechanical properties, and their applications, in com-
parison with biogenic and other biomaterials.
2. Overview of bioceramics and other biomaterials
definitions and classification of biomaterials
When a man-made material is placed within the human
body, tissue reacts towards the implant in a variety of ways
depending on the material type. The mechanism of tissue in-
teraction (if any) depends on the tissue response to the im-
plant surface. In general there are three terms in which a
biomaterial may be described in or classified into represent-
ing the tissues responses. These are bioinert, bioresorbable,
and bioactive.P'<' The term bioinert refers to any material
that once placed in the human body has minimal interaction
with its surrounding tissue, examples of these are stainless
steel, titanium, alumina, partially stabilised zirconia, and
ultra high molecular weight polyethylene. Generally a fi-
brous capsule might form around bioinert implants hence its
biofunctionality relies on tissue integration through the im-
plant.
Bioactive refers to a material, which upon being placed
within the human body interacts with the surrounding bone
and in some cases, even soft tissue. This occurs through a
time-dependent kinetic modification of the surface,
triggered by their implantation within the living bone. An
ion-exchange reaction between the bioactive implant and
surrounding body fluids results in the formation of a
biologically active hydrocarbonate apatite (calcium phos-
phate) layer on the implant that is chemically and crystal-
lographically equivalent to the mineral phase in bone. Prime
examples of these materials are synthetic hydroxyapatite
[CalO(P04)6(OHh],5),6) glass-ceramic A-W7) and bio-
glass@.8)
Bioresorbable refers to a material that upon placement wi-
thin the human body starts to dissolve (resorbed) and slow-
ly replaced by advancing tissue (such as bone). Common
examples of bioresorbable materials are tricalcium phos-
phate [Ca3 (P04) 2 ] and polylactic-polyglycolic acid
copolymers. Calcium oxide, calcium carbonate and gypsum
are other common materials that have been utilised during
the last two decades. There are four basic classes of materi-
als used in clinical practice for biomedical implants and
devices. Those being, bioceramics, metallic alloys, poly-
mers and their composites. These classes of materials have
combinations of properties determined by the composition
and the production methods utilised, while each set of
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properties has its own benefits and limitations.
Bioceramics , , 1
Bioceramics used singularly or with addltlonal natura , ~r-
ganic or polymeric materials are, amongst, the mo~t pror~lls-
ing of all biomaterials. Interest m ceramics for blOmedlCal
applications has increased over the last twe?tyfiv~ years.
Ceramics are considered hard, brittle matenals with r~la-
tively poor tensile properties with excellent compressl:,e
strength, high resistance to wear with favourably low fric-
tional properties. The low frictional ~~ope:tles IS enhanc~d
by the fact that ceramics are hydrop~llIc Wlt~good wetta~ll-
ity and can be highly polished which provl~es a su~en?r
load bearing surface with itself or polymenc matenal m
physiologic environment. " . . ,
The ceramics that are used in Implantation and chmcal
purposes include aluminum oxide (alumina), partially
stabilised zirconia (PSZ) (both yittria [Y-TZP] and mag-
nesia stabilised [Mg-PSZ]), bioglasses, glass-ceramics, cal-
cium phosphates (hydroxyapatite and p-tricalcium phos-
phate) and crystalline or glassy forms of carbon and its com-
pounds.
Alumina is used for orthopaedic and dental implants it has
the ability to be polished to a high surface finish accompa-
nied by its bioinert property in physiological conditions and
high hardness it has been implemented in wear bearing
environments.Pv' An example of which has been stated
above where it has been implemented in total hip arthroplas-
ties (THA) as the femoral head generating reductions in
wear particles from ultra-high molecular weight polyethy-
lene (UHMWPE). Other applications for alumina encom-
pass porous coatings for femoral stems, porous alumina
spacers (where bone excavation has been necessary) and in
dentistry for tooth implants,!O)-12)
Compared to alumina, Mg-PSZ has higher flexural bend
strength, fracture toughness and Weibull modulus, as well
as lower Young's modulus and the ability to be polished to a
superior surface finish.P' The higher fracture toughness is
of importance in femoral heads due to the tensile stresses in-
duced by the taper fit onto the femoral stem. Although not
quite as hard as alumina, Mg-PSZ still possesses excellent
wear resistance and has been proposed and used for similar
orthopaedic applications as alumina.F' Wear rates of
UHMWPE against magnesia partially stabilised zirconia
have been found to be low enough such that tribological
debris would not be a problem in clinical applications.w-v'
Preliminary results indicate that the use of a ceramic-cera-
mic femoral head/acetabular cup system is advantageous
over ceramic/UHMWPE systems as polymeric wear debris
is avoided.l'" In fact Chevalier et a1.17)found that the co-
efficient of friction between an alumina cup and zirconia
head was much lower than ceramic against UHMWPE, and
the resultant wear between the two components was almost
zero. Recent work by Clarke et al.1S) on articulation of
femoral heads in total hip replacement (THR) using hip
simulators with alpha-calf serum as a lubricant, which alu-
mina/alumina, zirconia/alumina, and zirconia/zirconia cou-
ples were investigated has shown that wear rates using zir-
conia/ zirconia exhibit a mild run-in phase as opposed to a
more evident run-in phase when comparing to alumina/ alu-
mina articulation, followed by little observable weight
change thereafter. Typically alumina/alumina wear rev-
ealed steady weight loss trend after a run-in phase, While
zirconia/alumina wear, where zirconia was the head and the
liner alumina, showed little weight loss and the alumina
linear revealed a typical run-in phase followed by stead-state
weight loss. The study has revealed promise for hard/hard
THR systems whereby wear rates were three times less in
order of magnitude when compared to PE cups. The study
has employed an alpha-calf serum at a 50% concentration
whereby most other studies published w~re carried out ,:s-
ing either water or saline solutlon which. c~n be q~llte
detrimental to the performance of the cerarmc .m question
The glasses that have been investigated ,for implantauon
are primarily based on silica (Si02), which may contam
small amounts of other crystalline phas~s.. T~e mo;t
prominent and successful applic.ation ?f this IS Bioglass ,
which can be found in detail m van?,:s co~~rehenslve
reviews.4),18J-20lBioactive glass composltlOns lie in the ~ys-
tern CaO-P20s-Si02. The first development of.such a b~og-
lass began in 1971 when Hench firs~proposed hIS45S5 blO~
lass with a composition of 45% SI02, 24.5% CaO, 24.5 0
Na02, and 6% P20S by weight." Hench,4J and Vrouwenvel-
der et a1.,21)suggested that bioglass 45S5 has gr~ater os-
teoblastic activity as compared to hydroxyapatite. The
reasoning behind this was due to a rapid exchange of alkali
ions at the surface, which in turn over a period of time leads
to the formation of a silica rich layer. This then allows for
the migration of Ca2+ and P043- ions to the silica rich sur-
face where they combine with soluble calcium and phos-
phate ions from the solution, where the formation of an
amorphous CaO-P20S layer takes place. This layer under-
goes crystallisation upon the interaction of OH-, COi- and
F- from solution. Similar phenomenon have been observed
by other researchers of bioglass with similar composi-
tions. 22),23)
Li et a1.,24)prepared glass ceramics from a similar compo-
sition with differing degrees of crystallinity and found that
the amount of glassy phase remaining directly influences the
formation of an apatitic layer, with total inhibition when the
glassy phase constituted less than about 5 mass%. Due to
the surface-active response of these types of materials, they
have been accepted as bioactive (or surface-active) bio-
materials and have found applications in middle ear im-
plants and other non-load bearing conditions.
Calcium phosphate ceramics were proposed as early as
the 1920 for biomedical applications because tri-calcium
phosphate, injected into defects, demonstrated more rapid
bone growth and union than the untreated defects.
Hydroxyapatite (HAp) was first identified as being the
mineral component of bone by DeJong.2S) However, it
was not until the 1970s that synthetic hydroxyapatite
[CalQ(P04) 2(OH)z] was accepted as a potential biomaterial
that forms a strong chemical bond with bone in vivo, while
remaining stable under the harsh conditions encountered in
the human body.
Hydroxyapatite and p-tricalcium phosphate [P-Ca3
(P04)z] are the primary calcium phosphates that have been
implemented as biomaterials. p-tricalcium phosphates have
been used successfully, as fillers for bone defects to stimu-
late the formation of new bone.26) However, this study
showed that after a 12 month period, p-tri-calcium phos-
phate was observed to have been totally absorbed. It is
thought that these calcium phosphates could be used as im-
plants or as bone replacement/defect fillers. It was aimed
that these materials will be used to fill voids in bone struc-
ture that will dissolve over a period of time while the resorp-
tion takes place, and the bone re-growth or advancement
takes place at similar rates. These properties place hydrox-
yapatite and other calcium phosphates into the class of inor-
ganic biomaterials known as bioactive materials.F" The only
other inorganic materials that fall into this highly specialized
classification are the biocompatible glasses and glass cera-
mics (Table 1).
The dissolution rates of some of these materials under
simulated physiological conditions have been investigated
with emphasis placed on hydroxyapatite, p-tricalcium phos-
phate and tetra-calcium phosphate. Under in vitro condi-
tions, the solubility of these materials has been shown to
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Table 1. Solubility Products of Various Calcium Phosphate Com-
pounds
Chemical Abbr. Chemical Phase CalF Space Solubility
Name Formula Group Product
Monocalciwn MCP Ca(H2PO.). - 0.50 - I.OxIO·'
PhosphateHydrate H,O
DicalciumPhosphateDCPD CaHPO•. Brushite 1.00 21m 1.87xlO-7
Hydrate 2H,O
DicalciumPhosphateDCPA CaHPO. Monetite 1.00 PI 1.26xlO·7
Aohydrous
OctacaIciumPhos- OCP C".H,(po.). 133 5.01x10-"
phatePentahydrate 5H2O
(l-Tricalcium TCP Ca,(pO.), (l-Whit- 1.50 R3c 2.83xlO-'"
Phosphate lockite
Penta-calcium HAp Ca,(pO.),OHHydroxy- 1.67 P6,Jm 2.35xlO-"
HydroxylPhosphate Apatite
Tetra-caJcium TCPM Ca.O(PO.), Hilgen- 2.00 P2,
PhosphateMonoxide stoekite
decrease in the order of:28l.29)
Tetra-calcium phosphate> P-Tricalcium Phosphate >
Hydroxyapatite
It has been stated that hydroxyapatite is "scarcely
resorbable"30),31) and therefore, hydroxyapatite's potential
to be implemented for osseous implant purposes is justified.
Metallic alloys
Metallic alloys have proved themselves as excellent
biomaterials due to their properties in fracture fixation
(Table 2). There are three main metallic alloys that have
been established as suitable for orthopaedic implants. Those
being low carbon steel alloys (316L stainless steel), cast
cobalt based alloys (cobalt chrome and molybdenum), and
titanium (commercially pure or titanium alloy-aluminium
6%, vanadium 4% (Ti6Al4V)). Of which their biocom-
patibility has been well understood and dccumented.lv-V'
Of the three, titanium when mixed in the ratio of
Ti-13Nb-13Zr, has been reported to be particularly out-
standing in their ability to form a hard, abrasion - resistant
ceramic surface layer with an oxidative treatment and have
improved biocompatibility.33)-35J New generation zirconia
surface converted zirconium metal for ceramic knee applica-
tions is one of the most recent additions into this highly com-
petitive field.
Fracture fixation of an implant includes screws, plates,
nails, and their various mutations and combinations. These
implants require biocompatibility and the requirements of
strength, ductility and elasticity. Because of these require-
ments and the usually applied fixation methods, if too rigid
there is an increased probability of bone resorption and pos-
sible bone fracture when the implant is removed during a re-
vision surgery.
Titanium alloys (Ti6A14 V and Ti-13Nb-13Zr) have the
benefit of good strength to weight ratio and are relatively in-
ert in the human body, and the sensitivity are rare.
Ducheyne et al.36J found that even though vanadium and
aluminium are released over time within the body, there was
no appearance of any adverse reaction. Their modulus of
elasticity and specific gravity are half that of stainless steel
and cobalt chromium alloys-?' (d. Table 2). The effect of
stress shielding with the use of titanium alloys is rare and
therefore, the implant does not generally have to be re-
moved from the patient and lower specific gravity imparts
lighter and less obtrusiveness to the recipient.P' However,
tissue discolouration observed during revision surgery has
generated a common resistance from the orthopaedic frater-
nity.
Polymers
Most types of polymers used for biomedical purposes
are homopolymers: polymethylmethacrylate (PMMA), 2-
hydroxethyl methylmethacrylate (HEMA or PHEMA),
polyethylene (PE) , polypropylene (PP), nylon, polydi-
methyl siloxane (PDMS), polytetrafluoroethylene (PTFE).
Others are copolymers: polyglycolide lactide (PGL), hexa-
fluoropropylene (FEP), and polyurethanes (PU). Due to
the chemical compositions and molecular structure,
UHMWPE and high-density polyethylene (HDPE), and re-
cent cross-linked polyethylene (HCPE) are the most stable
polymers available for implant use (bioinert).
A good example of the use of HDPE is the total hip
replacement carried out in 1962 by Charnley, where the
HDPE was used for the acetabular CUp.39) This particular
design has continued and in early 70's a metal alloy stem
was employed with an alumina femoral head on a
UHMWPE acetabular cup. This design during the last 25
Table 2. Mechanical Properties of Biomaterials
YOUNGS COMPRESSIVE TENSILE POISSONS DENSITY FRACTURE HARDNESS
MODULUS STRENGTH STRENGTH RATIO glem3 TOUGHNESS Knoop
GPa MPa MPa MPam'12
METALS
Titanium Alloy (Ti-6AI-4V) 114 450-1850 900-1172 0.34 4.43 44 -66 3200
Cr-Co-Mo 210 480-600 400-1030 0.29 8.3 120-160 3000
Stainless Steel (316L) 193 515-620 0.30 8.0 20 -95
CERAMICS
Alumina 420 4400 282-551 0.27 3.98 3- 5.4 2300
Zirconia (TZP) 210 1990 800-1500 0.31 5.74-6.08 6,4-10.9 1400
Silicon Nitride (HPSN) 304 3700 700-1000 0.30 3.3 3.7 - 5.5 1600
Hydroxyapatite (3% porosity) 7-13 350-450 38-48 3.05-3.15
HUMAN TISSUE
Cortical Bone 3.8-11.7 88-164 82-114 0.28 1.7-2.0 2-12 130-170
Cancellous Bone 0.2-0.5 23 10-20 0.32
Cartilage 0.002-0.01 5-25
OTHER
Bone Cement (PMMA) 2.24-3.25 80 48-72 1.19 0.7-1.6
UHMWHD Polyethylene 0.69 20 38-48 0.20 0.94
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years has reportedly reduced wear rates by as much as 10 to
20 times40),4l) as compared to wear rates metal-on-metal
alone. It has been widely reported that, wear particles
produced during articulation can cause severe tissue reac-
tion, abrasion, and eventual loosening of the implant, which
is accompanied by severe discomfort to the patient and revi-
sion surgery is required. However, some recent reports
based on some of the metal/metal implants', 30 years sur-
vival success, somehow rekindled a new interest in the use
of highly polished metal/metal hip implant use in both Eu-
rope and USA markets.
Composites
During the last 5 years bone cement materials has grown
in popularity and are a very promising osteoconductive sub-
stitutes for bone graft. They are prepared like acrylic ce-
ments and contains range of powders such as mono calcium
phosphate, tri calcium phosphate and calcium carbonate,
which is mixed in a solution of sodium phosphate. These ce-
ments are produced without polymerisation and the reaction
is nearly non-exothermic. The final compounds are reported
to be 10-100 MPa in compression while 1-10 MPa in ten-
sion although very weak under shear forces. It is currently
used in orthopaedics in the management of fractures. It has
been suggested that this material could improve the com-
pressive strength of the vertebral bodies in osteoporosis. In-
jection of calcium phosphate cement is feasible and it may
improve their compressive strength.v"
Preparation of hydroxyapatite / ceramic composites
through the addition of various ceramic reinforcements has
been attempted, metal fibres,43) Si3N4or Alz03 whiskers.w
Al203 platelets45),46)and Zr02 particles.47),48)In many cases,
the composites could not be successfully prepared and, be-
cause of problems related to a poor densification, the
mechanical properties could not be improved.
Hydroxyapatite/metal and hydroxyapatite/polymer com-
posites are two typical classes of materials, which have been
examined for improving the toughness characteristics of
synthetic hydroxyapatite.w'<" In both cases, a toughness
improvement can be found, due to a crack-face bridging
mechanism operated upon plastic stretching of metallic or
polymeric ligaments. This mechanism is the same as that
which improves the toughness characteristics of natural
bones above those of synthetic (dense) hydroxyapatite. 53)
Zhang et al.54)proposed a toughened composite consisting
of calcium hydroxyapatite dispersed with silver particles.
This material was obtained by a conventional sintering
method. It was reported that the toughness of these compo-
sites increased up to 2.45 MPa'm1/2 upon loading the mix-
ture with 30 vol% Ag. The use of silver is not only for tak-
ing advantage of the ductility of silver in terms of fracture
toughness, but also because silver is inert and has anti-
bacterial properties.F" de With and Corbijn-?' used metal
(Hastelloy X and Fe-Cr-alloy) fibres as reinforcement for
hydroxyapatite. Some of their composites could be fully
densified by hot-pressing at temperatures below the decom-
position temperature of hydroxyapatite to tricalcium phos-
phate and tetracalcium phosphate. Fracture toughness was
improved by a factor 6 as compared with monolithic hydrox-
yapatite material, with a maximum value of 7.4 MPa'm1/2
for the FeCr-alloy-containing composite. The bending
strength of this composite was also higher (i.e., > 200
MPa) than that of monolithic hydroxyapatite. However,
despite the improvements in strength and toughness, the
benefit of a composite structure on other mechanical proper-
ties, above other monolithic ceramics or metals does not
seem to be universally accepted.
3. Processing of hydroxyapatites for
biomedical applications
Bone grafts
Bone grafting is currently used in orthopaedic and maxil-
lofacial surgery for the treatment of bridging diaphyseal
defects, non-union, filling metaphyseal defects and man-
dibular reconstruction. Autogeneous bone graft is osteogen-
ic (which have an inherent capacity to form bone, due to liv-
ing cells such as osteocytes or osteoblasts), osteoconductive
(have no capacity to form bone or induce its formation but
they provide an inert scaffold which osseous tissue can uti-
lise to regenerate living bone), osteoinductive (stimulate
cells in the wound to undergo phenotypic conversion to os-
teoprogenitor cell types capable of formation of bone).
There are no substitutes for autogenous bone; there are,
however, synthetic alternatives. Allografts have been used
as an alternative, but it has low or no osteogenicity, in-
creased immunogenicity and resorbs more rapidly than au-
togenous bone; most importantly, transmission of disease
remains a concern.
In clinical practice, fresh allografts are rarely used be-
cause of immune response and the risk of transmission of
disease. The frozen and freeze-dried types are osteoconduc-
tive but are considered, at best, to be only weekly osteoin-
ductive. Freeze drying diminishes the structural strength of
the allograft and renders it unsuitable for use in situations in
which structural support is required. Allograft bone is a use-
ful material in patients who require bone grafting of a non-
union but have inadequate autograft bone. Bulk allografts
can be utilised for the treatment of segmental bone
defects. 56)Their use is well documented for reconstruction
after resection of bone tumours, however not common in
reconstruction after trauma in which bone lengthening and
transport are usually required.
Composites for graft applications
Demineralised bone matrix (DBM) can induce heterotop-
ic bone, the active components of DBM being a series of
glycoproteins, which belong to a group of transforming
growth factor superfamily (TGF-P). The members of this
superfamily are responsible for the morphogenetic events
involved in the development of tissue and organs. A protein
can be isolated from the bone matrix, which is termed as the
bone morphogenic protein (BMP). DBM is commercially
available and used in management of non-union of fractures.
They are not suitable where structural support is required.
To date, the main delay in developing clinical products has
been the need to find a suitable carrier to deliver the BMP to
the site at which its action is required. New generation
ceramic composites/hybrids could fill this gap. Experimen-
tally, BMP-2 and OP-1 (BMP-7) have been shown to
stimulate the formation of new bone in diaphyseal defects in
the rat, rabbit, dog, sheep and non-human primates. 57)The
use of BMP's with new calcium phosphate derivatives or
composites could be used for bone remodelling where bone
regeneration and remodelling is needed such as therapeutic
applications in osteoporosis.
Bovine collagen may be mixed with hydroxyapatite and is
marketed as a bone-graft substitute, which can be combined
with bone marrow aspirated from the site of the fracture.
Although no transmission of disease has been recorded,
their use will continue to be a source of concern. This
material is osteogenic, osteoinductive and osteoconductive,
however it lacks the structural strength required.
Calcium Sulphate (Plaster of Paris) or its composites are
one of the oldest osteoconductive materials available. They
have been used to fill bony defects however its main draw-
back is the chemical reaction that occurs during setting
which results in non-homogeneous crystalline structure with
variable properties. It also resorbs very rapidly at a rate,
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which exceed the capacity of surrounding bone to regener-
ate.
Hydroxyapatite coatings from simulated body fluids
One of the most promising methods in bioceramics has
been the introduction of simulated body fluids (SBF) by
Kokubo and co-workers.581,59! A hydroxyapatite layer can be
easily produced on various organic or inorganic substrates
in an acellular simulated body fluid with ion concentrations
nearly equal to those of the human blood plasma. 58 I Further
analysis of the surfaces showed that it contained very fine
crystallites of carbonate ion containing apatite (Fig. 1). Os-
teoblasts have been shown to proliferate and differentiate on
this apatite layer.s? Subsequent chemical bond can generate
a faster healing and longevity.
Body fluid is a metastable solution and if an apatite
nucleating functional group is present on a substrate within
the body fluid, the apatite spontaneously nucleates. It has
been reported that this nucleation rate increases if excessive
Ca2~ ions, P04H2 , and Si-OH, Ti-OH, Zr-OH, Ta-OH,
Nb-OH or similar functional groups are present.v"
Hydroxyapatite coatings by sol-gel and other methods
Due to the reason that porous hydroxyapatite has un-
favourable mechanical properties it is not used as a
monolithic structure for implantation under load bearing
purposes. This has seen the investigation of hydroxyapatite
being used as a thin film coating on metallic alloys. Because
hydroxyapatite is bioactive, using it as a thin film on
biometallic alloys enables the coupling of the two materials
primary properties to form a functional single component.v!'
Of the metallic alloys investigated titanium based alloys
have shown to be the material of preference for thin film
coating.V' Titanium alloys possesses good mechanical
strength and fatigue resistance under load bearing condi-
tions. They tend to be lightweight, with high strength to
weight ratios and it is not uncommon for these alloys to be
three to four times stronger than aluminium.
Of the coating techniques investigated, thermal spraying
tends to be the most commonly used and analysed. This
technique has been faced with challenges of producing a
controllable resorption response in clinical situations. Be-
Fig. 1. SEMmicrographof apatite formationon silicaand titania
gels in SBF solution (after Kokuboet al.59,).
sides the set backs, thermally sprayed coatings are con-
tinually being improved. However, other techniques are
being investigated. A driving factor behind these other tech-
niques can be attributed to the finding on sputtered hydrox-
yapatite coatings that only a submicrometric coating thick-
ness is sufficient to simulate carbonate apatite deposition
under in vivo conditions.F"
Techniques that are capable of producing thin coatings in-
clude pulsed-laser depositions- and sputtering'v' which, like
thermal spraying involves high-temperature processing,
Other techniques such as electrodeposition'<' ,67 and
sol-gel681 utilise lower temperatures and avoid the challenge
associated with the structural instability of hydroxyapatite
at elevated temperatures.F"
The sol-gel technique is categorised as an intermediate
temperature method, which, like other methods has the abil-
ity to produce either an amorphous or crystalline coating.
However, the key factors are that it results in a
stoichiometrically homogeneous coating due to mixing on
the molecular scale; reduced firing temperatures due to
small particles sizes with high surface areas; ability to
produce uniform fine-grained structures; use of different
chemical routes (alkoxide or aqueous based); and their ease
of application to complex shapes with a range of coating
techniques those being dip, spin, and spray coating."?' The
lower processing temperature is an added advantage, it
avoids the phase transition (~883°C) in the titanium (based
alloys) used for biomedical devices.
Coralline apatites by hydrothermal method
These materials are derived from the sea coral. The pore
structure of coralline calcium phosphate produced by cer-
tain species is similar to human cancellous bone, making it a
suitable material for bone graft (Fig. 2).
Coral is composed of calcium carbonate in the form of
aragonite. As coral is a naturally occurring structure it has
optimal strength and structural characteristics. Coral has
been used as bone grafts and orbital implants since the
1970s as the porous nature of the structure allows in-growth
of blood vessels to create a blood supply for bone, which will
eventually infiltrate the implant. Pore interconnection sizes
are of utmost importance when hard and soft tissue in-
growth is involved. Kuhne et al."!' showed that implants
with average pore sizes of around 260 Jim had the most suc-
cessful in-growth as compared to no implants (simply leav-
ing the hole empty). It was reported that the interaction of
Fig. 2. Corallinestructure after conversionto hydroxyapatite.






Fig. 3. Schematic diagram of the in situ polymerisation synthesis route.
heat
the primary osteons between the pores via the interconnec-
tions that allows propagation of osteoblasts.
The hydrothermal method was first used in 1974, for
hydroxyapatite formation directly from corals by Roy et
al. 72)It was reported that complete replacement of aragonite
(CaC03) by phosphatic material was achieved under 270°C
and 103 MPa using the hydrothermal process. In 1996, HAp
derived from Indian coral using hydrothermal process was
reported by Sivakumar et al.73) However, the resultant
material was in the form of a powder and required further
forming and shaping. Hydroxyapatite is said to replace the
aragonite whilst preserving the porous structure. During the
hydrothermal treatment the following exchange takes place:
10CaC03 + 6 (NH4) 2HP04 + 2H20
---+CalO(P04)6(OH) 2+ 6 (NH4hC03 + 4H3C03
(1)
The resulting material is known as coralline hydroxyapatite,
whether in the porous coralline structure or in powdered
form.
Hu et al.74)succeeded to convert Australian coral to 100%
hydroxyapatite by using the hydrothermal method and a
patented process based on alkoxide sol gel coating. They
have reported 120% increase in the biaxial strength of the
treated coral in comparison to unconverted one.
Novel processing routes to biomimetic hybrid compo-
sites
The conventional way to synthesize an inorganic material-
based composite is to subject a mixture of the constituent
phases to heat treatment. This process is also common in
the biomaterials production field, however, it is conceptually
far from the biomineralization process from body fluids
which occurs in nature. The natural process makes it availa-
ble fine hybrid structures, which are hardly reproducible by
sintering. In recent years, several research groups have
demonstrated the feasibility of in vitro techniques for the
synthesis of biomimetic material structures.58),75)-78)
However, the superior sophistication of the biological route
has not been paired yet and these techniques, so far, with an
exception of Kokubo's very inventive SBF method, have not
proved to be fully applicable for actual use.
Obviously, a traditional sintering route is not directly ap-
plicable to produce ceramic/polymer composites because no
polymer will stand at the densification temperature of any
ceramic material.
Dense hybrid materials were obtained, opening a com-
pletely new perspective in biomaterials for artificial bone
substitutes.P' A new alternative route, based on an in situ
polymerization process, carried out into an inorganic
scaffold with submicrometer-sized open porosity, has been
recently proposed. 52),53)This method is an intermediate one
between conventional sintering and biomineralization ex
vitro, because it still employs sintering for the preparation of
the inorganic scaffold, but the subsequent hybridisation of
the scaffold with organic phases is carried out through a
chemical route, thus avoiding high-temperature heating
procedures. This method enables the synthesis of biomimet-
ic (hybrid) inorganic/organic composites and while aiming
at a relatively complex structural designs, it is based on a
simple and easily reproducible process. A schematic of this
efficient synthesis route is given in Fig, 3.
4. Fracture behavior and toughening mechanisms in
biogenic materials and synthetic composites
A common characteristic of natural biomaterials such as
bone,80)nacre.s!' sea urchin tooth82) and other tough hybrid
materials in nature is the strong microscopic interaction be-
tween the inorganic and the organic phases. This charac-
teristic allows the organic phase to act as a plastic energy-
dissipating network, forming stretching (bridging) liga-
ments across the faces of a propagating crack. In biological
materials, the crack-face bridging mechanism is governed
by structures hierarchically designed at a nanoscale level.
Such complexity has led to the common perception that, in
considering which methods can be used to mimic natural de-
sign, in situ synthesis techniques should be adopted.
Precipitation in situ of calcium carbonate or hydroxyapatite
into a polymeric matrix, for example, has been proposed as
a novel synthetic route to biomimetic composites.75l.831
Despite significant advances in understanding biological
mineralization and developing new fabrication processes,
the composites to date obtained by these methods are by far
in embryo for actual applications, due to their low structural
performance.
Figure 4 shows the results of fracture tests carried out on
two natural biomaterials, bovine femur and Japanese nacre
(Crassostrea Nippona), in comparison with a synthetic
hydroxyapatite/nylon-6 composite (obtained by in situ
polymerisation of e-caprolactam infiltrated into a porous
apatite scaffold) and a dense monolithic apatite obtained by
sintering. The higher work of fracture achieved in
inorganic/ organic hybrid materials, as compared to that of
the dense monolithic hydroxyapatite, is due to stretching of
protein or polymeric ligaments across the crack faces during
fracture propagation (Fig. 5).
Although the microscopic architecture of human
manufactured composites will still remain behind that of
natural materials, mimicking natural microstructures while
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Fig. 4. Results of fracture tests carried out on two natural
biomaterials, bovine femur and Japanese nacre (CrassostreaNippo-
na), in comparison with a dense synthetic hydroxyapatite obtained
by traditional sintering, and a synthetic hydroxyapatite/nylon-S
composite obtained by in situ polymerisation of e-caprolactam in-
filtrated into a porous apatite scaffold.
Fig. 5. Protein and polymeric ligaments stretched across the
crack faces during fracture propagation in (a) Japanese nacre,
(b) bovine femur, and (c) hydroxyapatite/nylon-S composite.
using strong synthetic molecules may lead to a new genera-
tion of synthetic biomimetic materials, whose toughness
characteristics are comparable with the toughest materials
available in nature. A formidable challenge remains the op-
timisation of bioactivity characteristics in these novel hybrid
composites.
5. Conclusions
In this paper, we have revisited some of the key-issues
related to both processing and applications of bioceramics
as compared with other available biomaterials. We believe
that with an improved physical insight into microscopic
phenomena and understanding of stress related mechan-
isms, major fundamental issues in the biomedical field,
which stand still unsolved, can be further investigated and
new insights achieved. However, this will require a more in-
tense collaboration among medical doctors, ceramists, phys-
icists and technologists to achieve substantial team-work in
the bioceramics field. We hope to contribute with this over-
view to promote in the near future collaborations both na-
tionally and internationally (e.g., between Japan and Aus-
tralia) to trigger substantial improvements in this complex
and important field.
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